Routine data analysis for moderate hemolysis interference correction in neuron specific enolase quantification
Biochemia medica · 2025
DOI: 10.11613/bm.2025.020802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemia medica, 2025. Verfasst von Leyre Ruiz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Phosphopyruvate Hydratase, Hemolysis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Serum neuron specific enolase (NSE) is used as neuroendocrine tumor and central nervous system damage marker. It is present in variable concentrations in erythrocytes and hemolysis interferes in serum NSE quantification. Our aim was to develop a correction formula for moderate hemolysis, based on repeated patient samples instead of artificial sample doping with hemolysates. Materials and methods: We searched in laboratory informatics system for patients with sample pairs obtained within 24 h, for NSE quantification. We registered NSE and hemolytic index (NSE1 and HI1) from the first moderate hemolyzed sample (HI: 15-80), and from the second non-hemolyzed sample obtained afterwards (NSE2 and HI2). In a development cohort (N = 41), we obtained the formula NSEcalc = NSE1 - (0.354 x (HI1 - HI2)) - 0.162, which was later used in the validation cohort (N = 26) to calculate NSE corrected concentrations (NSEcalc).
Results
Concentrations of NSE2 differed from NSE1 (P = < 0.001) but not from NSEcalc (P = 0.291). In 84% samples, NSE1 had a relative bias from NSE that exceeded the 14% limit of total error allowable, with a median relative bias of 22.5%. Meanwhile, the bias between NSE2 concentrations and NSEcalc was - 0.4 µg/L (95% confidence interval = - 3.8 to 4.5), the relative bias was 8.3% and only 23% of samples exceeded the 14% limit. Formula usefulness was limited to moderate hemolytic samples.
Conclusions
In summary, with this innovative approach, the NSEcalc bias is low enough to have clinical significance, so re-drawings of blood samples might be avoided. This approach also opens the possibility to correct the estimation of other magnitude concentrations affected by in vitro hemolysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
- Science Faculty, Universidad de Navarra, Pamplona, Spain.
- Service of Biochemistry, Cancer Center Clínica Universidad de Navarra, Pamplona, Spain.
- IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
Zitieren
APA
Ruiz, L., Munoz, T., González, A., & Alegre, E. (2025). Routine data analysis for moderate hemolysis interference correction in neuron specific enolase quantification. Biochemia medica. https://doi.org/10.11613/bm.2025.020802
Vancouver
Ruiz L, Munoz T, González A, Alegre E. Routine data analysis for moderate hemolysis interference correction in neuron specific enolase quantification. Biochemia medica. 2025. doi:10.11613/bm.2025.020802
BibTeX
@article{Ruiz2025,
author = {Ruiz, Leyre and Munoz, Tomás and González, Alvaro and Alegre, Estibaliz},
title = {Routine data analysis for moderate hemolysis interference correction in neuron specific enolase quantification},
journal = {Biochemia medica},
year = {2025},
doi = {10.11613/bm.2025.020802}
}
EUVIMED